Canaccord Genuity analyst Kyle Mikson has reiterated a 'Buy' rating for Twist Bioscience (TWST) and increased its price target from $90 to $120. This indicates a positive outlook from the analyst, suggesting potential upside for the stock.
Canaccord Genuity analyst Kyle Mikson has maintained a 'Buy' rating on Twist Bioscience and raised the price target from $90 to $120. This analyst action signals increased confidence in the company's future performance and valuation. Investors in Twist Bioscience are directly affected, as this positive analyst coverage could lead to increased investor interest and potentially a short-term upward movement in the stock price. While not a fundamental change in the company's operations, such analyst upgrades can influence market sentiment and provide a positive catalyst for traders looking for short-term opportunities. The long-term implications depend on whether the company's actual performance justifies the raised price target.